Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Market Structure ? Growth Drivers ? Restraints and Challenges ? Emerging Product Trends & Market Opportunities ? Porter?s Fiver Forces The trend and outlook of global market is forecast in optimistic, ...

Europe pharmaceutical manufacturing industry market was valued at $2.84 billion in 2022 and will grow by 8.6% annually over 2022-2032. The growth is driven by the increased drug approvals, increasing ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Wall Street analysts weigh in on Amazon, Nvidia, Carnival, Seagate Technology Holdings, Netflix, and Affirm Holdings.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...